Request Sample

Global Biosimilars Industry Overview | By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides), By Type of Manufacturing (In-house Manufacturing, Contract Manufacturing) By Disease (Oncology, Blood Disorders, Chronic Diseases, Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases)- Global Industry Opportunity and Current Growth Analysis 2019-2025

Description

Global Biosimilars Industry was valued at USD $7.75 Billion in the year 2019. Global Biosimilars  Industry is further estimated to grow at a CAGR of 6.0% from 2019 to reach USD $40.85 Billion by the year 2025. Top-down and bottom-up approaches were used to estimate and validate the size of the Industry and to estimate the size of various other dependent subIndustrys. The overall Industry size was used in the top-down approach to estimate the sizes of other individual subIndustrys (mentioned in the Industry segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the Industry segment revenues obtained. Various secondary sources such as World Health Organization, US Food and Drug Administration, Centers for Disease Control and Prevention, and European Commission have been used to identify and collect information useful for this extensive commercial study of the biosimilars Industry.

 

Major market players in Biosimilars Industry are Pfizer, Sandoz, Teva Pharmaceuticals, Amgen, Biocon, Dr. Reddy’s Laboratories, Celltrion, amsung Biologics, CP Guojian Pharma, Biotech Pharma, Celgen Pharma, Henlius.

 

Biosimilars Industry, By Product

  • Recombinant Non-glycosylated Proteins
  • Insulin
  • Recombinant Human Growth Hormone
  • Granulocyte Colony-stimulating Factor
  • Interferons
    • Interferon-Beta
    • Interferon-Alpha
  • Recombinant Glycosylated Proteins
  • Erythropoietin
  • Monoclonal Antibodies
    • Rituximab
    • Infliximab
    • Adalimumab
    • Other Monoclonal Antibodies
  • Follitropin
  • Recombinant Peptides
  • Glucagon
  • Calcitonin

 

Biosimilars Industry, By Type of Manufacturing

  • In-house Manufacturing
  • Contract Manufacturing

 

Biosimilars Industry, By Disease

  • Oncology
  • Blood Disorders
  • Chronic Diseases
  • Autoimmune Diseases
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Diseases

 

Biosimilars Industry Overview, By Region

North America

• USA

• Canada

Europe

• Germany

• U.K.

• France

• Italy

• Rest of Europe

APAC

• China

• India

• Japan

• Rest of Asia-Pacific

RoW

• Latin America

• Middle East & Africa

Find About Us

Contact Us

Dispatch Center

Global Reports Store Pune (India)

Operational & Marketing Center

Manjari(bk), Hadapsar, Pune 412307

Payment

Copyright © 2019 Global Reports Store All rights reserved.